Drug delivery system provider Aptar Pharma has collaborated with local digital therapeutics firm Propeller Health to introduce a comprehensive platform for the development of digital medicines across various therapeutic areas and diseases.
The platform will integrate software with connected drug delivery device expertise in order to improve treatment effectiveness and clinical outcomes for patients.
The platform will cover inhaled, injectable, nasal and dermal medicine delivery.
Under the alliance, Aptar will combine its device development, manufacturing and packaging experience with Propeller’s platform as well as design and implementation expertise for digital therapeutics.
The partners intend to collaborate with other pharmaceutical and healthcare organisations to better develop, manufacture and commercialise digital medicines for certain marketed and pipeline brands.
Aptar Pharma president Salim Haffar said: “Aptar Pharma has been providing innovative drug delivery systems for nearly 50 years, helping billions of patients around the world.
“Today, we are excited to broaden our offerings as we continue this journey towards improved patient care and clinical outcomes by growing our partnership with Propeller Health, the leader in their field of digital therapeutics.”
Aptar has also strategically invested $10m in Propeller Health during a recent funding round.
The companies plan to co-market the digital medicine platform. Under the arrangement, Propeller will manage the digital services, while Aptar will be responsible for the device development, manufacturing and supply chain.
Propeller Health co-founder and CEO David Van Sickle said: “We’re excited to expand our relationship with Aptar and apply our expertise to new diseases. Our end-to-end infrastructure enables fast, flexible and secure development and commercialisation of digital medicines.”
Digital medicines are designed for personalised treatment, real-time monitoring, detection of day-to-day disease changes and enhancing patient adherence. They are expected to primarily increase patient outcomes and minimise healthcare costs.